Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Get Free Report) traded down 1.3% on Thursday . The stock traded as low as $3.84 and last traded at $3.90. 3,226 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 16,827 shares. The stock had previously closed at $3.95.
Genenta Science Stock Down 4.5%
The company's fifty day moving average is $3.97 and its two-hundred day moving average is $4.00.
Hedge Funds Weigh In On Genenta Science
Large investors have recently bought and sold shares of the business. Allianz SE acquired a new position in Genenta Science in the fourth quarter valued at approximately $444,000. Citadel Advisors LLC acquired a new stake in Genenta Science in the fourth quarter worth $46,000. Finally, Algebris UK Ltd raised its holdings in Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock worth $368,000 after purchasing an additional 55,000 shares during the period. 15.13% of the stock is currently owned by institutional investors and hedge funds.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
See Also
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
